Sotorasib

Unassigned

New Medicines

Metastatic, KRAS G12c mutated non-small cell lung cancer (NSCLC) - second-line therapy or greater

Information

New molecular entity
Amgen
Amgen

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

An orally bioavailable potent and selective KRAS G12C covalent small molecule inhibitor
RAS(G12C) mutation in KRAS accounts for 11% of all KRAS mutations in cancer [1].
Metastatic, KRAS G12c mutated non-small cell lung cancer (NSCLC) - second-line therapy or greater
Oral

Further information

Yes
To be confirmed

Evidence based evaluations